Skip to content

Study · Randomized controlled trial · 2020

1 result

Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study.

Jeppesen PB, Gabe SM, Seidner DL, Lee HM, Olivier C

Clinical nutrition (Edinburgh, Scotland)9 Nov 2019Cited by 18 (Europe PMC)

PMID31784300 (opens in a new tab)DOI10.1016/j.clnu.2019.11.001 (opens in a new tab)PepBankPUB-31784300
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In all studied SBS-IF subgroups, teduglutide produced numerically greater plasma citrulline increases at Week 24 than placebo.

    In plain wordsIn all studied SBS-IF subgroups, teduglutide increased blood citrulline numerically more than placebo.

    Peptide
    Teduglutide
    Outcome
    IncreasePlasma citrulline at Week 24
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Intestinal Function · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In all subgroups, patients treated with teduglutide showed numerically greater increases in plasma citrulline at Week 24 compared with placebo.
    3 context sentences
    Summary · context
    A post hoc analysis of plasma citrulline levels from patients in the STEPS 24-week study of teduglutide in patients with SBS-IF.
    Summary · context
    Plasma citrulline was assessed in all patients; patients were stratified 3 times into subgroups based on bowel anatomy, cause of SBS-IF, and baseline PS volumes.
    Title · context
    Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00798967

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

Shiren = 8625 Nov 2008 to 25 Jan 2011

Short Bowel Syndrome

Trial pageClinicalTrials.govUpdated 3 Jun 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.